Vimarsana
Biggest News Aggregation in the World

Page 10 - Rezolute Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rezolute Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rezolute Inc Today - Breaking & Trending Today

Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by HC Wainwright - Vimarsana News

Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by HC Wainwright

Rezolute (NASDAQ:RZLT – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Monday, TipRanks reports. They currently have a $21.00 price objective on the stock. A number of other equities research analysts also recently commented on the stock. Roth Capital lifted their target price on […]

Rezolute, Inc. (NASDAQ:RZLT) SVP Brian Kenneth Roberts Buys 21,052 Shares of Stock - Vimarsana News

Rezolute, Inc. (NASDAQ:RZLT) SVP Brian Kenneth Roberts Buys 21,052 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT – Get Rating) SVP Brian Kenneth Roberts purchased 21,052 shares of the stock in a transaction dated Wednesday, May 4th. The stock was acquired at an average cost of $3.80 per share, with a total value of $79,997.60. Following the transaction, the senior vice president now directly owns 21,052 shares in the […]

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market - Vimarsana News

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Rezolute, Inc. Announces Aggregate $130 Million Registered - Vimarsana News

Rezolute, Inc. Announces Aggregate $130 Million Registered

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism - Press Release - Vimarsana News

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism - Press Release

Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-